REGENXBIO Inc. (Nasdaq:RGNX) and Dimension Therapeutics, Inc. (Nasdaq:DMTX) today announced that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction.
{iframe}http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=RssLanding&cat=news&id=2295626{/iframe}